{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T08:51:41.472236+00:00","company":{"ticker":"TSHA","cik":1806310,"company_name":"Taysha Gene Therapies, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"1eed4de4f6eacec294e26aa0ca83c4464dfb2599","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-02T20:05:28+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"38,973,186","subject":null,"votes_abstain":"67,607","votes_against":null,"votes_for":"203,825,717","votes_withheld":null}]},"claim":"Taysha Gene Therapies, Inc. shareholders approved Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 4 : Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 360,924 630,378 67,607 Broker Non-Votes: 38,973,186","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-253478","anchor_url":"https://secwatch.observer/filing/0001193125-26-253478#claim-1eed4de4f6eacec294e26aa0ca83c4464dfb2599","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0a268124772ae38110ab5d44e4f9277461c07a6e","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-02T20:05:28+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"38,973,186","subject":null,"votes_abstain":"345,291","votes_against":"36,396,784","votes_for":"168,142,551","votes_withheld":null}]},"claim":"Taysha Gene Therapies, Inc. shareholders approved Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 3 : Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 36,396,784 345,291 Broker Non-Votes: 38,973,186","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-253478","anchor_url":"https://secwatch.observer/filing/0001193125-26-253478#claim-0a268124772ae38110ab5d44e4f9277461c07a6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm"},{"fact_type":"shareholder_vote","fact_key":"66cc74049d08d00d4bf3a31ef8c20382cd6e80da","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-02T20:05:28+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"18,176","votes_against":"25,551","votes_for":"243,814,085","votes_withheld":null}]},"claim":"Taysha Gene Therapies, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 2 : Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 25,551 18,176 Broker Non-Votes: 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-253478","anchor_url":"https://secwatch.observer/filing/0001193125-26-253478#claim-66cc74049d08d00d4bf3a31ef8c20382cd6e80da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2a127d8c780bd836f4855fa63b720bf4b29e5f11","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-02T20:05:28+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-01","outcome":"passed","proposal_text":"Election of two nominees to serve as directors until the 2029 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"38,973,186","subject":"Sean P. Nolan","votes_abstain":null,"votes_against":null,"votes_for":"169,142,295","votes_withheld":"35,742,331"},{"broker_non_votes":"38,973,186","subject":"Laura Sepp-Lorenzino, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"150,094,517","votes_withheld":"54,790,109"}]},"claim":"Taysha Gene Therapies, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 169,142,295 35,742,331 Laura Sepp-Lorenzino, Ph.D. 150,094,517 54,790,109 Broker Non-Votes: 38,973,186 Both nominees were elected.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-253478","anchor_url":"https://secwatch.observer/filing/0001193125-26-253478#claim-2a127d8c780bd836f4855fa63b720bf4b29e5f11","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm"},{"fact_type":"earnings_release","fact_key":"6452773e2b2ac9283dc6f4ee8fbb9ed28096e604","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":null},"claim":"Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 6, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2026, and recent business highlights.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-207633","anchor_url":"https://secwatch.observer/filing/0001193125-26-207633#claim-6452773e2b2ac9283dc6f4ee8fbb9ed28096e604","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/0001193125-26-207633-index.htm"},{"fact_type":"governance_change","fact_key":"c95637abd338de86f0119b9cab91db7195a88e7d","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-06-03T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-02","item_codes_triggered":["5.03"],"summary_text":"Increase in authorized common stock from 400,000,000 to 700,000,000"},"claim":"Taysha Gene Therapies, Inc.: Increase in authorized common stock from 400,000,000 to 700,000,000 (effective 2025-06-02).","evidence_excerpt":"At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Amendment ”) to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-133745","anchor_url":"https://secwatch.observer/filing/0001193125-25-133745#claim-c95637abd338de86f0119b9cab91db7195a88e7d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525133745/0001193125-25-133745-index.htm"},{"fact_type":"earnings_release","fact_key":"893dd7fb7d0fda179eb0395f445d439ebefcae0f","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-138253","anchor_url":"https://secwatch.observer/filing/0001193125-24-138253#claim-893dd7fb7d0fda179eb0395f445d439ebefcae0f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/0001193125-24-138253-index.htm"},{"fact_type":"earnings_release","fact_key":"bb08038cf268a6b13f4ce7d0886f8df97a1bbfcb","cik":1806310,"ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-03-19T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full Year 2023","report_date":"2024-03-19","result_type":"reported_results","revenue_text":null},"claim":"Taysha Gene Therapies, Inc. reported financial results for Full Year 2023.","evidence_excerpt":"On March 19, 2024, Taysha Gene Therapies, Inc. (the \" Company \") reported financial results for the year ended December 31, 2023 and recent business and clinical updates.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-24-071321","anchor_url":"https://secwatch.observer/filing/0001193125-24-071321#claim-bb08038cf268a6b13f4ce7d0886f8df97a1bbfcb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/0001193125-24-071321-index.htm"}]}